Passive versus electrotransport-facilitated transdermal absorption of ketorolac

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 3, 1998, Pages 303-315

  Park, Kyungsoo ^b   Verotta, Davide ^b   Gupta, Suneel K ^b   Sheiner, Lewis B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

KETOROLAC;

ABSORPTION; ADULT; ARTICLE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TRANSDERMAL DRUG ADMINISTRATION; VOLUNTEER;

ADMINISTRATION, CUTANEOUS; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BIOLOGICAL TRANSPORT, ACTIVE; HUMANS; KETOROLAC; LINEAR MODELS; MALE; REFERENCE VALUES; SKIN; STEREOISOMERISM; TIME FACTORS; TOLMETIN;

EID: 0031894637     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90162-X     Document Type: Article

References (18)

1. Cobelli C, Mari A, Del Prato S, De Kreutzenberg S, Nosadini R, Jensen I. Reconstructing the rate of appearance of subcutaneous insulin by deconvolution. Am J Physiol 1987;253:E584-90.
2. Cutler DJ. Numerical deconvolution by least squares: use of polynomials to represent the input function. J Pharmacokinet Biopharm 1978;6:243-63.
3. Vaughan DP, Dennis M. Mathematical basis of point-area deconvolution method for determining in vivo input functions. J Pharm Sci 1978;67:663-5.
4. Verotta D. An inequality-constrained least-squares deconvolution method. J Pharmacokinet Biopharm 1989;17:269-89.
5. Verotta D. Concepts, properties, and applications of linear systems to describe the distribution, identify input, and control endogenous substances and drugs in biological systems. Crit Rev Bioeng 1996;24:73-139.
6. DeBoor C. A practical guide to splines. New York: Springer-Verlag; 1978.
7. Hayball PJ, Wrobel J, Tamblyn JG, Nation RL. The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. Br J Clin Pharmacol 1994;37:75-8.
8. Mroszczak E, Combs D, Chaplin M, Tsina I, Tarnowski T, Rocha C, et al. Chiral kinetics and dynamics of ketorolac. J Clin Pharmacol 1996;36:521-39.
9. Vakily M, Corrigan B, Jamali F. The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats. Pharm Res 1995;12:1652-7.
10. Combs D, Mroszczak E, Juan D, Ipe D, Yu S, Rocha C. Application site and gender differences in pharmacokinetics for a ketorolac tromethamine transdermal delivery system [abstract]. Clin Pharmacol Ther 1995; 57:181.
11. Phipps J, Padmanabhan R, Lattin G. Iontophoretic delivery of model inorganic and drug ions. J Pharm Sci 1989;78:365-9.
12. Hayball PJ, Tamblyn YH, Wrobel J. Stereoselective analysis of ketorolac in human plasma by high-performance liquid chromatography. Chirality 1993;5: 31-5.
13. Beal SL, Sheiner LB. NONMEM users guides. San Francisco: NONMEM Project Group, UCSF; 1991.
14. Brocks DR, Jamali F. Clinical pharmacokinetics of ketorolac tromethamine. Clin Pharmacokinet 1992; 23:415-27.
15. Roy SD, Manoukian E, Combs D. Absorption of transdermally delivered ketorolac acid in humans. J Pharm Sci 1995;84:49-52.
16. Gordon MS, Chowhan Z. In vivo/in vitro correlations for four differently dissolving ketorolac tablets. Biopharm Drug Dispos 1996;17:481-92.
17. Gordon MS, Ling TL, Yee JP. Ketorolac tromethamine bioavailability via tablet, capsule, and oral solution dosage forms. Drug Dev Ind Pharm 1995;21:1143-55.
18. Kelm GR, Buchanan W, Meredith MP, Offenbacher S, Mankodi SM, Dobrozsi DJ, et al. Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. J Pharm Sci 1996;85:842-7.